Avotres

Avotres is a clinical-stage biotech pioneering a novel approach to restore immune self-tolerance. Its lead asset, AVT001, is a cell therapy targeting the Q/E CD8+ Treg pathway, with a completed Phase I/II trial in Type 1 Diabetes and plans for a Phase III trial, as well as a Phase IIb study in Multiple Sclerosis. The company's platform has the potential to address a broad spectrum of autoimmune conditions and transplant rejection, and it is also developing an early-stage monoclonal antibody, AVT002, for oncology. Backed by venture capital, Avotres is advancing a multi-asset pipeline toward high-value clinical milestones.

Platform centered on the Qa-1/HLA-E restricted CD8+ regulatory T cell (Q/E CD8+ Treg) pathway and the 'Avidity Model of Peripheral T Cell Regulation' for restoring immune self-tolerance.

Avotres competes in the crowded autoimmune and immuno-oncology spaces against large pharma and numerous biotechs. Its key differentiation is its novel, antigen-agnostic approach to restoring tolerance, but it must demonstrate superior efficacy or safety to established and emerging therapies.